Evidence map›Paper›PMID 39984977›Full record

ArticleBMC medicine2025

Multi-cancer early detection based on serum surface-enhanced Raman spectroscopy with deep learning: a large-scale case-control study.

Yuxiang Lin, Qiyi Zhang, Hanxi Chen, Shuhang Liu, Kaiming Peng, Xiaojie Wang, Liyong Zhang, Jun Huang, Xiuqing Yan, Xueliang Lin and 5 more

Abstract read
In one paragraph

Article in BMC medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Article
  12. Review
  13. Review
  14. Review
  15. Review
  16. Article
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Yuxiang Lin *Department of Breast Surgery, Fujian Medical University Union Hospital, Fuzhou, Fujian Province, 350001, China.
Qiyi Zhang *Network Technology Center, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, Fujian Province, 350003, China.
Hanxi Chen *Department of Breast Surgery, Fujian Medical University Union Hospital, Fuzhou, Fujian Province, 350001, China.
Shuhang LiuKey Laboratory of Optoelectronic Science and Technology for Medicine of Ministry of Education, Fujian Provincial Key Laboratory of Photonics Technology, Fujian Normal University, Fuzhou, Fujian, 350117, China.
Kaiming PengDepartment of Thoracic Surgery, Fujian Medical University Union Hospital, Fuzhou, Fujian Province, 350001, China.
Xiaojie WangDepartment of General Surgery, Fujian Medical University Union Hospital, Fuzhou, Fujian Province, 350001, China.
Liyong ZhangDepartment of General Surgery, Fujian Medical University Union Hospital, Fuzhou, Fujian Province, 350001, China.
Jun HuangDepartment of Laboratory Medicine, Fujian Medical University Union Hospital, Fuzhou, Fujian Province, 350001, China.
Xiuqing YanDepartment of Nursing, Fujian Medical University Union Hospital, Fuzhou, Fujian Province, 350001, China.
Xueliang LinFujian Provincial Key Laboratory for Advanced Micro-Nano Photonics Technology and Devices, Institute for Photonics Technology, Quanzhou Normal University, Quanzhou, 362000, China.
Uddin M D HasanDepartment of Clinical Medicine, Fujian Medical University, Fuzhou, Fujian, 350122, China.
Mahabub SarwaraDepartment of Clinical Medicine, Fujian Medical University, Fuzhou, Fujian, 350122, China.
Fangmeng FuDepartment of Breast Surgery, Fujian Medical University Union Hospital, Fuzhou, Fujian Province, 350001, China. ffm@fjmu.edu.cn.
Shangyuan FengKey Laboratory of Optoelectronic Science and Technology for Medicine of Ministry of Education, Fujian Provincial Key Laboratory of Photonics Technology, Fujian Normal University, Fuzhou, Fujian, 350117, China. syfeng@fjnu.edu.cn.
Chuan WangDepartment of Breast Surgery, Fujian Medical University Union Hospital, Fuzhou, Fujian Province, 350001, China. dr_chuanwang@fjmu.edu.cn.

Funding

Fuzhou Science and Technology Major Project 2023-ZD-004National Natural Science Foundation of China 62205179National Natural Science Foundation of China 82203781
6 · The paper itself

Abstract

backgroundEarly detection of cancer can help patients with more effective treatments and result in better prognosis. Unfortunately, established cancer screening technologies are limited for use, especially for multi-cancer early detection. In this study, we described a serum-based platform integrating surface-enhanced Raman spectroscopy (SERS) technology with resampling strategy, feature dimensionality enhancement, deep learning and interpretability analysis methods for sensitive and accurate pan-cancer screening.

methodsTotally, 1655 early-stage patients with breast cancer (BC, n = 569), lung cancer (LC, n = 513), thyroid cancer (TC, n = 220), colorectal cancer (CC, n = 215), gastric cancer (GC, n = 100), esophageal cancer (EC, n = 38), and 1896 healthy controls (HC) were enrolled. The serum SERS spectra were obtained from each participant. Data dimension enhancement was conducted by heatmap transformation and continuous wavelet transform (CWT). The dimensionalization SERS spectral data were subsequently analyzed by residual neural network (ResNet) as convolutional neural network (CNN) algorithm. Class activation mapping (CAM) method was performed to elucidate the potential biological significance of spectral data classification.

resultsAll participants were divided into a training set and a test set with a ratio of 7:3. The BorderlineSMOTE method was selected as the most appropriate resampling strategy and the deep neural network (DNN) model achieved desirable performance among all groups (accuracy rate: 93.15%, precision rate: 88:46%, recall rate: 85.68%, and F1-score: 86.98%), with the generated AUC values of 0.991 for HC, 0.995 for BC, 0.979 for LC, 0.996 for TC, 0.994 for CC, 0.982 for GC, and 0.941 for EC, respectively. Furthermore, the combination use of SERS spectra data and ResNet (form of heatmap) were also capable of effectively distinguishing different categories and making accurate predictions (accuracy rate: 94.75%, precision rate: 89.02, recall rate: 86.97, and F1-score: 87.88), with the AUC values of 0.996 for HC, 0.995 for BC, 0.988 for LC, 0.999 for TC, 0.993 for CC, 0.985 for GC, and 0.940 for EC, respectively. Additionally, strong wave number range of the spectral data was observed in the CAM analysis.

conclusionsOur study has offered a highly effective serum SERS-based approach for multi-cancer early detection, which might shed new light on cancer screening in clinical practice.

Indexed as

Deep LearningEarly Detection of CancerNeoplasmsSpectrum Analysis, RamanAdultAgedCase-Control StudiesFemaleHumansMaleMiddle AgedNeural Networks, ComputerConvolutional neural networkDeep neural networkMulti-caner early detectionRaman spectroscopySerum

Identifiers

PMID39984977
PMCPMC11846373

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.